Risk in drug trials

Lancet

Volumn 368, Issue 9554, 2006, Pages 2205-

  Barnes, Michael R ^a   Holbrook, Joanna ^a   Feild, John A ^b   Searls, David B ^b   Sanseau, Philippe ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD28 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TGN1412;

CLINICAL PROTOCOL; DRUG SCREENING; HUMAN; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; ANIMAL; BINDING SITE; MACACA; METABOLISM; NOTE; SPECIES DIFFERENCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; BINDING SITES; HUMANS; MACACA FASCICULARIS; MACACA MULATTA; RISK ASSESSMENT; SPECIES SPECIFICITY;

EID: 33845681632     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69882-6     Document Type: Letter

References (2)

1. Kenter M., and Cohen A. Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet 368 (2006) 1387-1391
2. Schneider C., Kalinke U., and Lower J. TGN1412: a regulator's perspective. Nat Biotechnol 24 (2006) 493-496